Prescribed medications recorded at registry inclusion.
| Medication, n (%) | N=277 |
| Antifibrotic prescribing | |
| Antifibrotics | 192 (69.3) |
| Pirfenidone | 186 (67.2) |
| Nintedanib | 6 (2.2) |
| Medication prescribed for IPF other than antifibrotics | |
| N-acetylcysteine | 48 (17.3) |
| Corticosteroids | 23 (8.3) |
| Azathioprine | 1 (0.4) |
| Ambrisentan | 1 (0.4) |
| Medication prescribed for indications other than IPF | |
| GERD therapy | 153 (55.2) |
| Antihypertensives | 151 (54.5) |
| Antithrombotics/anticoagulants | |
| Full anticoagulation* | 25 (9.0) |
| Full antiaggregation† | 16 (5.8) |
| Prophylactic treatment‡ | 100 (36.1) |
| Statins | 98 (35.4) |
| Corticosteroids | 4 (1.4) |
| Methotrexate | 1 (0.4) |
| Other | 218 (78.7) |
| Medication prescribed for indications other than IPF co-prescribed with pirfenidone§ | |
| Antihypertensives | 102 (54.8) |
| Antithrombotics/anticoagulants | |
| Full anticoagulation* | 17 (9.1) |
| Full antiaggregation† | 10 (5.4) |
| Prophylactic treatment‡ | 68 (36.6) |
| Statins | 69 (37.1) |
| Corticosteroids | 2 (1.1) |
| Other | 147 (79.0) |
*e.g. Vitamin K antagonists, full-dose low-molecular-weight heparins, novel oral anticoagulants.
†e.g, Clopidogrel.
‡e.g. Aspirin, low-dose low-molecular-weight heparins.
§Medication prescribed concomitantly with pirfenidone (denominator=186 [number of patients prescribed pirfenidone at baseline]).
GERD, gastro-oesophageal reflux disease; IPF, idiopathic pulmonary fibrosis.